Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance.
The relations of persistent tardive dyskinesia (TD) to glucose tolerance and family history of type 2 diabetes mellitus (FH-NIDDM) were examined in 22 schizophrenic patients. All patients underwent a standard oral glucose tolerance test (GTT) while receiving haloperidol, and 15 patients also underwent a GTT when drug free. Fasting blood glucose (FBS) was significantly higher in the TD group than in the non-TD group in the medicated condition, but not in the drug-free state. TD and non-TD groups did not differ significantly in postload glucose levels either in the drug-free or in the medicated condition. However, relative to the drug-free state, haloperidol-treated TD patients showed decreased glucose tolerance while non-TD patients showed increased glucose tolerance. Seven (32%) of the 22 patients had an FH-NIDDM. A positive FH-NIDDM was significantly associated with the presence of TD and with higher drug-free FBS. A possible role of melatonin in mediating the TD-augmenting effects of FH-NIDDM and the neuroleptic-induced decrease in glucose tolerance has been proposed.
Department of Clinical Neuropsychiatry, New York State Psychiatric Institute, NY 10032.
S
S
Mukherjee
S D
SD
Roth
R
R
Sandyk
D B
DB
Schnur
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000235:genetics*; D004409:Dyskinesia, Drug-Induced / Q000097:blood / Q000235:genetics*; D005260:Female; D005951:Glucose Tolerance Test; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000235:genetics*
D001786:Blood Glucose; D006220:Haloperidol